Wegovy has a list price of about $1,349 to $1,865 per month depending on the pharmacy, but most people pay significantly less. The actual cost ranges from $0 with qualifying insurance to $499 per month through the manufacturer’s self-pay program. What you’ll spend depends on your insurance status, whether you qualify for assistance programs, and which alternatives you’re willing to consider.
The Sticker Price vs. What People Actually Pay
Wegovy’s retail list price sits around $1,349 to $1,865 for a 28-day supply, depending on the dose and pharmacy. That number rarely reflects what patients actually hand over at the counter. In early 2025, Novo Nordisk (the company behind Wegovy) cut its self-pay price by 23%, bringing the out-of-pocket cost to $499 per month for people without insurance coverage. This price applies regardless of dose strength, since Wegovy costs the same whether you’re on the lowest starter dose or the full maintenance dose.
For people with commercial insurance that covers the drug, Novo Nordisk offers a savings card that can reduce costs to as little as $25 per month, saving up to $1,001 per fill off the retail price. To use it, your insurance plan needs to already cover Wegovy in some capacity.
What Insurance Typically Requires
Getting insurance to cover Wegovy is rarely as simple as getting a prescription. Most commercial plans attach several conditions to approval. A review of major U.S. health plans found that the vast majority require a BMI above 30, or a BMI above 27 combined with at least one weight-related health condition like type 2 diabetes, high blood pressure, or sleep apnea. A couple of plans set even stricter thresholds above 30 for all patients.
Beyond weight criteria, eight out of the reviewed plans required patients to be using Wegovy alongside a reduced-calorie diet, increased physical activity, or other lifestyle changes. Seven plans required enrollment in a behavioral modification program, with most requiring that enrollment before the drug would be approved. One plan also required patients to try and fail on a different weight-loss medication first.
Even after initial approval, continued coverage isn’t guaranteed. Every plan that reported continuation criteria required documented weight loss of at least 4% to 5% from baseline to keep the prescription authorized. Two plans also required patients to show their BMI had dropped to 25 or below.
If Your Insurance Denies Coverage
Denials are common, but they’re not always the final word. About 44% of insurance denials are successfully overturned on appeal. The process starts with reading your explanation of benefits carefully to understand the specific reason for the denial. That reason shapes how you build your case.
An effective appeal letter, ideally prepared with your doctor, should explain why Wegovy is medically necessary for your situation. Useful supporting evidence includes documentation of previous weight-loss methods that didn’t work, records showing how your weight contributes to other health conditions, and if you’ve already started the medication, data on how much weight you’ve lost so far. If your plan was created after March 2010, you have a legal right to request this reconsideration.
Medicare Coverage
Medicare Part D historically did not cover weight-loss medications. That changed partially in March 2024, when Wegovy received FDA approval for reducing the risk of serious cardiovascular events in patients who have obesity or overweight combined with established cardiovascular disease. Medicare Part D now covers Wegovy for that specific combination of conditions. If you’re on Medicare and looking for Wegovy purely for weight management without cardiovascular disease, standard Part D coverage still won’t apply unless your plan offers it as an enhanced benefit.
Free Wegovy Through Patient Assistance
Novo Nordisk runs a Patient Assistance Program that provides Wegovy at no cost to qualifying patients. Eligibility requires being a U.S. citizen or legal resident with a household income at or below 400% of the federal poverty level. You must either have Medicare or be uninsured entirely. People with private or commercial insurance don’t qualify, and neither do those enrolled in Medicaid, Medicare’s Low Income Subsidy program, or VA benefits.
If you’re uninsured and your income falls within your state’s Medicaid thresholds, you’ll need to apply for Medicaid first and submit a denial letter with your application. Medicare beneficiaries earning below 150% of the federal poverty level must similarly show proof they were denied Part D Extra Help. Once enrolled, uninsured patients receive 12 months of coverage, while Medicare patients are enrolled for a calendar year.
How Wegovy Compares to Zepbound
Zepbound, made by Eli Lilly, is Wegovy’s closest competitor. Its self-pay pricing is similar: $349 per month for the starter dose and $499 per month for higher doses through the company’s direct program. Both manufacturers cut prices in early 2025, landing at nearly identical out-of-pocket costs for uninsured patients at maintenance doses. Insurance coverage and copay structures may differ between the two, so it’s worth checking both with your specific plan.
Compounded Semaglutide
Compounded versions of semaglutide, the active ingredient in Wegovy, have been available through telehealth providers and compounding pharmacies at lower prices, typically advertised between $129 and $497 per month. These aren’t identical to brand-name Wegovy. They’re mixed by compounding pharmacies rather than manufactured by Novo Nordisk, and they haven’t gone through the same FDA approval process as the brand-name drug.
The advertised price often doesn’t include the full cost. Many telehealth platforms charge additional membership fees, prescriber consultation fees, and fees for required lab work. Factor those in before comparing directly to the $499 self-pay price for brand-name Wegovy. The FDA has also raised concerns about the safety and consistency of some compounded semaglutide products, so the lower price comes with trade-offs worth understanding.